Herd immunity in older adults from a middle-income country: A time-series trend analysis of community-acquired pneumonia mortality 2003-2017.

Carlos A Sanchez, Oriana Rivera-Lozada, Michelle Lozada-Urbano, Pablo Best-Bandenay
Author Information
  1. Carlos A Sanchez: Universidad Peruana de Ciencias Aplicadas Lima Peru. ORCID
  2. Oriana Rivera-Lozada: South American Center for Education and Research in Public Health Universidad Norbert Wiener Lima Peru. ORCID
  3. Michelle Lozada-Urbano: South American Center for Education and Research in Public Health Universidad Norbert Wiener Lima Peru. ORCID
  4. Pablo Best-Bandenay: School of Public Health and Administration Universidad Peruana Cayetano Heredia Lima Peru. ORCID

Abstract

Background and Aims: Community-acquired pneumonia is responsible for substantial mortality, and pneumococcus is commonly accepted as a major cause of pneumonia, regardless of laboratory confirmation. Child immunization programs have reported success in decreasing pneumonia mortality: directly in young children and indirectly (herd immunity) in unvaccinated adult populations in some countries. We assess changes in mortality trends for all-cause pneumonia in older adults associated with the introduction of pneumococcal vaccination for children in Peru.
Methods: This is a secondary analysis on administrative data collected periodically by the Peruvian Ministry of Health. An observational retrospective time series analysis was conducted using longitudinal population-based data from death certificates in Peru between 2003 and 2017. The time series includes 6 years before and 9 years after the introduction of the pneumococcal-conjugated vaccines in the national child immunization program in 2009. Monthly frequencies and annual rates for all-cause pneumonia deaths in children under 5 years of age and adults over 65 years of age are presented. Linear and quadratic trends are analyzed.
Results: deaths among older adults accounted for 75.6% of all-cause pneumonia mortality in Peru, with 94.4% of these reporting "pneumonia due to unspecified organism" as the underlying cause of death. Comparing pre- and post-child immunization program periods, annual average mortality rates from unspecified pneumonia decreased by 22.7% in young children but increased by 19.6% in older adults. A linear trend model supports this overall tendency, but a quadratic curve explains the data better.
Conclusion: Pneumococcal-conjugated vaccines are developed using serotypes prevalent in selected countries from less common (invasive) pneumococcal disease and expected to prevent mortality worldwide from widespread (noninvasive) pneumonia. Our results do not support the presence of herd immunity from pneumococcal vaccination of children for Community-acquired pneumonia in the increasingly ageing population of Peru. This should direct future research and could influence public health policy.

Keywords

References

  1. Clin Microbiol Infect. 2001 Nov;7(11):581-8 [PMID: 11737082]
  2. Pediatr Infect Dis J. 2013 Mar;32(3):203-7 [PMID: 23558320]
  3. Thorax. 2012 Jan;67(1):71-9 [PMID: 20729232]
  4. Epidemiol Rev. 1993;15(2):265-302 [PMID: 8174658]
  5. Vaccine. 2013 Dec 17;32(1):133-45 [PMID: 23684824]
  6. N Engl J Med. 2014 Oct 23;371(17):1619-28 [PMID: 25337751]
  7. Eur J Clin Microbiol Infect Dis. 1999 Dec;18(12):852-8 [PMID: 10691195]
  8. Wkly Epidemiol Rec. 2007 Mar 23;82(12):93-104 [PMID: 17380597]
  9. MMWR Morb Mortal Wkly Rep. 2005 Sep 16;54(36):893-7 [PMID: 16163262]
  10. J Infect Dis. 2013 Dec 1;208(11):1813-20 [PMID: 24092845]
  11. Curr Opin Pulm Med. 2009 May;15(3):223-9 [PMID: 19276811]
  12. N Engl J Med. 2015 Jul 2;373(1):92 [PMID: 26132954]
  13. Clin Ther. 2010 Aug;32(8):1517-32 [PMID: 20728764]
  14. N Engl J Med. 2015 Jul 30;373(5):415-27 [PMID: 26172429]
  15. Clin Ther. 2008 Feb;30(2):341-57 [PMID: 18343273]
  16. Int J Antimicrob Agents. 2011 Aug;38(2):108-17 [PMID: 21683553]
  17. Pharmacoeconomics. 2019 Sep;37(9):1093-1127 [PMID: 31025189]
  18. Ann Am Thorac Soc. 2016 Jun;13(6):933-44 [PMID: 27088424]
  19. Chest. 2018 Sep;154(3):628-635 [PMID: 29859184]
  20. JAMA. 2012 Feb 22;307(8):804-12 [PMID: 22357831]
  21. Lancet. 2007 Apr 7;369(9568):1179-86 [PMID: 17416262]
  22. N Engl J Med. 2015 Mar 19;372(12):1114-25 [PMID: 25785969]
  23. PLoS One. 2013 Aug 06;8(8):e71375 [PMID: 23940743]
  24. BMC Public Health. 2021 Sep 23;21(1):1731 [PMID: 34556065]
  25. Vaccine. 2017 May 19;35(22):2882-2891 [PMID: 28449971]
  26. Clin Infect Dis. 2017 Nov 13;65(11):1806-1812 [PMID: 29020164]
  27. Thorax. 2014 Feb;69(2):168-73 [PMID: 24048505]
  28. Trans R Soc Trop Med Hyg. 2014 Jun;108(6):326-37 [PMID: 24781376]
  29. Lancet Respir Med. 2019 Jan;7(1):10-11 [PMID: 30442586]
  30. Expert Rev Vaccines. 2020 Dec;19(12):1141-1151 [PMID: 33428494]
  31. BMJ. 2012 Oct 26;345:e6879 [PMID: 23103369]
  32. Health Sci Rep. 2023 May 03;6(5):e1224 [PMID: 37152218]
  33. Hum Vaccin Immunother. 2016;12(2):344-50 [PMID: 26647277]
  34. Lancet. 2007 Jul 21;370(9583):218-219 [PMID: 17658389]
  35. Medicine (Baltimore). 1990 Sep;69(5):307-16 [PMID: 2205784]
  36. Value Health Reg Issues. 2022 Mar;28:76-81 [PMID: 34801962]
  37. BMJ Open. 2018 Apr 10;8(4):e019439 [PMID: 29643153]
  38. mBio. 2011 Jan 25;2(1):e00309-10 [PMID: 21264063]
  39. N Engl J Med. 2003 May 1;348(18):1737-46 [PMID: 12724479]
  40. Semin Respir Infect. 1999 Jun;14(2):173-83 [PMID: 10391411]
  41. Wkly Epidemiol Rec. 2012 Apr 6;87(14):129-44 [PMID: 24340399]
  42. N Engl J Med. 2003 May 1;348(18):1747-55 [PMID: 12724480]
  43. Clin Infect Dis. 2004 Jul 15;39(2):170-2 [PMID: 15307024]
  44. J Am Geriatr Soc. 2020 May;68(5):1007-1014 [PMID: 31916246]
  45. PLoS One. 2013;8(4):e60273 [PMID: 23565216]
  46. Eur J Clin Microbiol Infect Dis. 2013 Mar;32(3):305-16 [PMID: 23242464]
  47. N Engl J Med. 2015 Jul 2;373(1):92 [PMID: 26132955]
  48. Hum Vaccin Immunother. 2016;12(2):417-20 [PMID: 26309055]
  49. Lancet. 2021 Sep 4;398(10303):906-919 [PMID: 34481570]
  50. Vaccine. 2003 May 16;21(17-18):1815-25 [PMID: 12706665]
  51. N Engl J Med. 1995 Dec 14;333(24):1618-24 [PMID: 7477199]
  52. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000422 [PMID: 23440780]

Word Cloud

Created with Highcharts 10.0.0pneumoniamortalitychildrenadultsPeruolderyearsimmunizationimmunityall-causepneumococcalanalysisdatacauseyoungherdcountriestrendsintroductionvaccinationtimeseriesusingdeathvaccinesprogramannualratesagequadratic6%unspecifiedtrendcommunity-acquiredpopulationBackgroundAims:Community-acquiredresponsiblesubstantialpneumococcuscommonlyacceptedmajorregardlesslaboratoryconfirmationChildprogramsreportedsuccessdecreasingmortality:directlyindirectlyunvaccinatedadultpopulationsassesschangesassociatedMethods:secondaryadministrativecollectedperiodicallyPeruvianMinistryHealthobservationalretrospectiveconductedlongitudinalpopulation-basedcertificates20032017includes69pneumococcal-conjugatednationalchild2009Monthlyfrequenciesdeaths565presentedLinearanalyzedResults:Deathsamongaccounted75944%reporting"pneumoniadueorganism"underlyingComparingpre-post-childperiodsaveragedecreased227%increased19linearmodelsupportsoveralltendencycurveexplainsbetterConclusion:Pneumococcal-conjugateddevelopedserotypesprevalentselectedlesscommoninvasivediseaseexpectedpreventworldwidewidespreadnoninvasiveresultssupportpresenceincreasinglyageingdirectfutureresearchinfluencepublichealthpolicyHerdmiddle-incomecountry:time-series2003-2017agedpneumococcus���conjugatedvaccine

Similar Articles

Cited By (4)